All In Biotech

Drug Trial Radar · NCT04689828

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 469 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

469

Actual

Start

Jun 15, 2021

Primary completion

Oct 2, 2022

Study completion Sep 9, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in Androgen receptor-directed therapy (ARDT) in metastatic castrate resistant prostate cancer (mCRPC) participants that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or mHSPC settings. 469 participants were randomized (235 in the 177Lu-PSMA-617 group and 234 in the ARDT group.

Conditions

  • Prostatic Neoplasms

Interventions

  • 177Lu-PSMA-617Drug

    administered intravenously once every 6 weeks (1 cycle) for 6 cycles

  • 68Ga-PSMA-11Drug

    single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 185 MBq (3 - 5 mCi).

  • ARDTDrug

    administered orally on a continuous basis, as per package insert and guidelines

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic Progression Free Survival (rPFS)Time frame: median FU (randomization to event or censoring) 3.65 months (range 0-12.3)

Locations

72 sites in 14 countries. Site status is shown where the registry gives one.

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • University of Florida

    Gainesville, Florida

  • Tulane Uni Health Sciences Center

    New Orleans, Louisiana

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Beth Israel Deaconess Med Ctr

    Boston, Massachusetts

  • WA Uni School Of Med

    St Louis, Missouri

  • Urology Cancer Center PC

    Omaha, Nebraska

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • NYU Laura and Isaac Perlmutter Cancer Center

    New York, New York

  • Mount Sinai Hosp Med School

    New York, New York

  • Memorial Sloan Kettering Cancer Ctr

    New York, New York

  • Duke Univ Medical Center

    Durham, North Carolina

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Tennessee Oncology

    Nashville, Tennessee

  • Uni Of TX MD Anderson Cancer Cntr

    Houston, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Onco Hemato Asso of SW Virginia

    Roanoke, Virginia

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Medical College Of Wisconsin

    Milwaukee, Wisconsin

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Innsbruck, Tyrol, Austria

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Liège, Belgium

  • Novartis Investigative Site

    Roeselare, West-Vlaanderen, Belgium

  • Novartis Investigative Site

    Vancouver, British Columbia, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Olomouc, Czechia

  • Novartis Investigative Site

    Angers, France

  • Novartis Investigative Site

    Bordeaux, France

  • Novartis Investigative Site

    Clermont-Ferrand, France

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Villejuif, France

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    München, Germany

  • Novartis Investigative Site

    Nijmegen, Netherlands

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.